It is therefore possible that an enhanced ability of the chimeric TBR-760 to bind with greater affinity or modulate activity of these heterodimers may contribute to the greater effect on tumor growth than the DA or SST agonists alone or in combination. Here, OGFR is linked to neoplasm.